[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334490-105":59,"doc-detail-334490-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","prognostic-and-predictive-value-of-angiogenesis-associated-serum-proteins-for-immunotherapy-in-esophageal-cancer","Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer","","Immune checkpoint inhibitors (ICIs) improve survival across cancers, yet in esophageal cancer responses occur only in subgroups and clinically useful predictive biomarkers remain limited. Plasma from 91 patients with esophageal cancer was collected before and after ICI therapy. Using Olink Immuno-Oncology proximity extension assays to measure 92 proteins, survival-related proteins were screened and a risk score model was built. Baseline IL-8, TIE2, and HGF levels associated with survival, and an angiogenesis-related risk score predicted prognosis and ICI response. Combination antiangiogenic therapy plus ICIs improved overall survival versus ICI monotherapy, supporting plasma proteome sequencing and future validation.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-and-predictive-value-of-angiogenesis-associated-serum-proteins-for-immunotherapy-in-esophageal-cancer/334490/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-and-predictive-value-of-angiogenesis-associated-serum-proteins-for-immunotherapy-in-esophageal-cancer/334490.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why are predictive biomarkers needed for esophageal cancer immunotherapy?","Question",{"text":112,"@type":113},"ICIs targeting anti-CTLA-4 and anti-PD-1 improve outcomes, but response rates in esophageal cancer are limited (about 10%–20%) and only a subset of patients benefit. Clinically useful biomarkers for optimal patient selection are lacking.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were angiogenesis-associated proteins measured in this study?",{"text":117,"@type":113},"Plasma samples from 91 patients were collected before and after ICI treatment. The Olink Immuno-Oncology panel (92 proteins) with proximity extension assays measured dynamic plasma protein changes and enabled biomarker screening.",{"name":119,"@type":110,"acceptedAnswer":120},"Which proteins formed the angiogenesis-related risk score, and what did it predict?",{"text":121,"@type":113},"The risk score was based on three angiogenesis-related proteins: IL-8, TIE2, and HGF. Baseline levels of these proteins were significantly associated with survival outcomes, and the resulting risk score predicted ICI response and prognosis.",{"name":123,"@type":110,"acceptedAnswer":124},"What was the effect of combining antiangiogenic therapy with ICIs?",{"text":125,"@type":113},"Antiangiogenic therapy combined with ICIs significantly improved overall survival compared with ICI monotherapy (p=0.044), supporting a potential therapeutic strategy alongside biomarker exploration.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},334490,1790142054,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Open access Original research  \n Prognostic and predictive value of  \nangiogenesis-associated serum proteins for immunotherapy in  \nesophageal cancer  \nMengting Gao  ,1 Xueying Wu  ,2,3 Xi Jiao,1 Ying Hu,2,3 Yanni Wang,1 Na Zhuo,1 Fengxiao Dong,1 Yujiao Wang,1 Fengyuan Wang,1 Yanshuo Cao,1 Chang Liu,1 Jian Li,4 Lin Shen  ,4 Henghui Zhang,2,3,5 Zhihao Lu1  \nTo cite: Gao M, Wu X, Jiao X, et al. Prognostic and predictive value of angiogenesisassociated serum proteins for immunotherapy in esophageal cancer. Journal for ImmunoTherapy of Cancer 2024;12:e006616 . doi:10 . 1136/ jitc-2022-006616  \n► Additional supplemental material is published online only. To view, please visit the journal online ([http://dx.doi.org/10](http://dx.doi.org/10) . 1136/jitc-2022-006616) .  \nAccepted 08 January 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Zhihao Lu; [pppeirain@126.com](pppeirain@126.com)  \nDr Henghui Zhang; [zhhbao@ccmu.edu.cn](zhhbao@ccmu.edu.cn)  \nProfessor Lin Shen; [shenlin@bjmu.edu.cn](shenlin@bjmu.edu.cn)  \nABSTRACT  \nBackground Immune checkpoint inhibitors (ICIs) have significantly improved patient survival in multiple cancers. However, therapy response in esophageal cancer is limited to subgroups of patients and clinically useful predictive biomarkers are lacking.  \nMethods We collected a series of plasma samples from 91 patients with esophageal cancer before and after ICI treatment. The Olink Immuno-Oncology panel (92 proteins) with proximity extension assays was used to detect the dynamic changes in plasma and potential biomarkers associated with treatment outcomes. We screened all survival-related proteins and established a risk score model to better predict the prognosis and treatment response in patients with esophageal cancer immunotherapy.  \nResults We found that 47 out of 92 quantified proteins had significant changes in plasma levels during ICI treatment (p\u003C0 .050), and these changed proteins were involved in immune-related reactions, such as intercellular adhesion and T-cell activation. Notably, the baseline levels of three angiogenesis-related proteins (IL-8, TIE2, and HGF) were significantly associated with the survival outcomes of patients treated with ICIs (p\u003C0 .050) . According to these prognostic proteins, we established an angiogenesisrelated risk score, which could be a superior biomarker for ICI response prediction. In addition, antiangiogenic therapy combined with ICIs significantly improved overall survival compared with ICI monotherapy (p=0 .044) .  \nConclusions An angiogenesis-related risk score based on three proteins (IL-8, TIE2, and HGF) could predict ICI response and prognosis in patients with esophageal cancer, which warrants verification in the future. Our study highlights the potential application of combining ICIs and antiangiogenic therapy and supports Olink plasma protein sequencing as a liquid biopsy method for biomarker exploration.  \nINTRODUCTION  \nEsophageal cancer is a high-incidence andidiopathic tumor in China and is the seventh most common cancer and the sixth most common cancer-related cause of death in the world.1 Most patients are diagnosed at  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ The immune checkpoint therapy has revolutionized the treatment of esophageal cancer. However, additional efforts should be made to investigate effective biomarkers for optimal patient selection.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ We identified angiogenesis-associated serum proteins, IL-8, TIE2, and HGF, which were associated with the prognosis of esophageal cancer patients treated by immunotherapy. Therefore, we established an angiogenesis-associated risk score containing these three proteins, which represent the immunosuppressive status and better predict the immune checkpoint inhibitor response in patients with esophag","cbCaipNOi8NbfTJh","https://ap.wps.com/l/cbCaipNOi8NbfTJh","pdf",7174047,11,"English","# Abstract\n# Introduction\n## Background on ICIs in esophageal cancer\n## Need for predictive biomarkers\n# Methods\n## Patient plasma collection and timing\n## Olink proximity extension assays\n## Protein screening and risk score construction\n# Results\n## Protein dynamics during ICI treatment\n## Baseline IL-8, TIE2, and HGF associations\n## Prognostic risk score performance\n## Antiangiogenic combination effects\n# Conclusions","[{\"question\":\"Why are predictive biomarkers needed for esophageal cancer immunotherapy?\",\"answer\":\"ICIs targeting anti-CTLA-4 and anti-PD-1 improve outcomes, but response rates in esophageal cancer are limited (about 10%–20%) and only a subset of patients benefit. Clinically useful biomarkers for optimal patient selection are lacking.\"},{\"question\":\"How were angiogenesis-associated proteins measured in this study?\",\"answer\":\"Plasma samples from 91 patients were collected before and after ICI treatment. The Olink Immuno-Oncology panel (92 proteins) with proximity extension assays measured dynamic plasma protein changes and enabled biomarker screening.\"},{\"question\":\"Which proteins formed the angiogenesis-related risk score, and what did it predict?\",\"answer\":\"The risk score was based on three angiogenesis-related proteins: IL-8, TIE2, and HGF. Baseline levels of these proteins were significantly associated with survival outcomes, and the resulting risk score predicted ICI response and prognosis.\"},{\"question\":\"What was the effect of combining antiangiogenic therapy with ICIs?\",\"answer\":\"Antiangiogenic therapy combined with ICIs significantly improved overall survival compared with ICI monotherapy (p=0.044), supporting a potential therapeutic strategy alongside biomarker exploration.\"}]","Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer | PDF",1790006866,28]